(secondQuint)Early Administration of Romidepsin and 3BNC117 in Treatment-nave HIV Patients Starting ART.

 The study will be conducted among ART naive HIV-1-infected patients.

 Subjects will continue ART while receiving LRA romidepsin and/or bNAb 3BNC117.

.

 Early Administration of Romidepsin and 3BNC117 in Treatment-nave HIV Patients Starting ART@highlight

To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent HIV-1 reservoir in treatment naive HIV-1 patients initiating antiretroviral therapy (ART)